Elucidating the effect of crystallization on drug release from amorphous solid dispersions in soluble and insoluble carriers

被引:25
|
作者
Ojo, Andrew Toye [1 ]
Ma, Congshan [1 ]
Lee, Ping, I [1 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, Toronto, ON M5S 3M2, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Amorphous solid dispersion; Crystallization; Dissolution performance; Itraconazole; Polymorphs; Soluble and insoluble carriers; PHASE-SEPARATION; PHYSICAL STABILITY; IN-VITRO; IMPACT; DISSOLUTION; SOLUBILITY; SUPERSATURATION; CLASSIFICATION; ITRACONAZOLE; PERFORMANCE;
D O I
10.1016/j.ijpharm.2020.120005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The development of amorphous solid dispersions (ASDs) is one way to overcome the bioavailability challenges of poorly water-soluble active pharmaceutical ingredients (APIs). An important consideration with ASD systems is that crystallization can occur during preparation, storage, and dissolution, thus reducing their bioavailability advantage. Currently, it is unclear whether the dissolution characteristics of the polymer carrier affects the dissolution performance of ASDs with intrinsic crystallization. Our aim was to differentiate the impact of a minor amount of intrinsic crystallinity (up to 10%) within soluble and insoluble carriers on ASD performance, using the area under the curve (AUC) values of non-sink dissolution profiles as a measure of dissolution performance that can inform in vivo bioavailability. In order to discern such differences, itraconazole (ITZ) ASDs were prepared by Hot Melt Extrusion (HME) with 50% (w/w) drug loading. PVP K12 and HPMCAS were used as the soluble and insoluble carriers in pH 1.2 dissolution media, respectively. Dissolution was also conducted in pH 6.8 buffer, wherein HPMCAS becomes soluble, to cross-validate experimental observations. Crystalline content was determined by differential scanning calorimetry (DSC) prior to dissolution. Soluble polymers differed from insoluble polymers in that crystals formed during processing and storage were released during dissolution which can undergo further growth causing a sharp decline in drug concentration in the dissolution medium. This led to a significant decrease in the AUC for soluble ASDs containing intrinsic crystallinity. In contrast, insoluble polymer carriers did not release the intrinsically formed crystals and the impact of subsequent crystal growth on dissolution performance was minimal for insoluble ASD systems. Furthermore, physical mixtures with spiked crystallinity were only found to reflect the dissolution performance of soluble ASDs exhibiting intrinsic crystallinity. Thus, in considering the impact of intrinsic crystallinity on ASD performance, the nature of the polymeric carrier in terms of solubility characteristics needs to be taken into account as there is significantly more variation in AUC with soluble carriers than insoluble carriers exhibiting intrinsic crystallinity.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Structural Modifications of Polyethylenimine to Control Drug Loading and Release Characteristics of Amorphous Solid Dispersions
    Kelsall, Kristen N.
    Foroughi, Leila M.
    Frank, Derek S.
    Schenck, Luke
    LaBuda, Anthony
    Matzger, Adam J.
    MOLECULAR PHARMACEUTICS, 2023, : 1779 - 1787
  • [32] Supersaturation and crystallization: non-equilibrium dynamics of amorphous solid dispersions for oral drug delivery
    Kawakami, Kohsaku
    EXPERT OPINION ON DRUG DELIVERY, 2017, 14 (06) : 735 - 743
  • [33] Evolution of supersaturation from amorphous solid dispersions in water-insoluble polymer carriers: Effects of swelling capacity and interplay between partition and diffusion
    Schver, Giovanna C. R. M.
    Nadvorny, Daniela
    Lee, Ping, I
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 581
  • [34] Development of novel darunavir amorphous solid dispersions with mesoporous carriers
    Zolotov, Sergey A.
    Demina, Natalia B.
    Zolotova, Anna S.
    Shevlyagina, Natalia V.
    Buzanov, Grigorii A.
    Retivov, Vasilii M.
    Kozhukhova, Evgeniia I.
    Zakhoda, Oleg Y.
    Dain, Igor A.
    Filatov, Andrei R.
    Cheremisin, Alexander M.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 159
  • [35] Advances in the development of amorphous solid dispersions: The role of polymeric carriers
    Zhang, Jie
    Guo, Minshan
    Luo, Minqian
    Cai, Ting
    ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 18 (04)
  • [36] Advances in the development of amorphous solid dispersions: The role of polymeric carriers
    Jie Zhang
    Minshan Guo
    Minqian Luo
    Ting Cai
    AsianJournalofPharmaceuticalSciences, 2023, 18 (04) : 47 - 81
  • [37] Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions
    Karavas, Evangelos
    Georgarakis, Emmanuel
    Sigalas, Michael P.
    Avgoustakis, Konstantinos
    Bikiaris, Dimitrios
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2007, 66 (03) : 334 - 347
  • [38] Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery - An update
    Jermain, Scott V.
    Brough, Chris
    Williams, Robert O., III
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2018, 535 (1-2) : 379 - 392
  • [39] HPMCAS as an effective precipitation inhibitor in amorphous solid dispersions of the poorly soluble drug candesartan cilexetil
    Oliveira Pinto, Juliana Munari
    Leao, Aline Franciane
    Riekes, Manoela Kluppel
    Franca, Maria Terezinha
    Stulzer, Hellen Karine
    CARBOHYDRATE POLYMERS, 2018, 184 : 199 - 206
  • [40] What Is the Mechanism Behind Increased Permeation Rate of a Poorly Soluble Drug from Aqueous Dispersions of an Amorphous Solid Dispersion?
    Frank, Kerstin J.
    Westedt, Ulrich
    Rosenblatt, Karin M.
    Hoelig, Peter
    Rosenberg, Joerg
    Maegerlein, Markus
    Fricker, Gert
    Brandl, Martin
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 103 (06) : 1779 - 1786